Combination therapy for treating mastocytosis
Combination therapy of c-KIT inhibitors and MAPKAP pathway inhibitors synergistically inhibits c-KIT mutant mastocytosis, achieving more efficient apoptosis and growth inhibition, solving the problem of limited therapeutic effects in existing technologies, and providing a more effective treatment option.
Patent Information
- Application Number
- CN202410805958.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-01-31
- Filing Date
- 2019-01-31
- Publication Date
- 2024-11-08
AI Technical Summary
In the existing technology, c-KIT inhibitors have limited efficacy in treating mastocytosis with c-KIT D816V mutation and have significant side effects. Secondary resistance mutations further reduce the therapeutic effect.
By combining c-KIT inhibitors with MAPKAP pathway inhibitors (such as MEK inhibitors, ERK inhibitors, or RAF inhibitors), apoptosis of mastocytosis cells can be induced. By combining compound A with MAPKAP pathway inhibitors such as trametinib and uritinib, cell proliferation and apoptosis can be synergistically inhibited.
It significantly increased the amount of apoptosis in c-KIT mutant mast cells, reduced mast cell accumulation in organs, inhibited cell growth and mediator release, provided more effective therapeutic effects, alleviated symptoms and potentially achieved a complete response or remission of mastocytosis.
Smart Images

Figure CN118903436A_ABST
Abstract
Description
[0001] This case is a divisional application of a case with an application date of January 31, 2019, an invention name of Combination Therapy for Treating Mastocytosis, and an application number of 2019800157174.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to USSN 62 / 624,453, filed on January 31, 2018, which is incorporated herein by reference in its entirety. Background Art
[0004] c-KIT (also referred to as KIT, CD117 and stem cell factor receptor) is a 145kDa transmembrane tyrosine kinase protein that serves as a type III receptor. The c-KIT proto-oncogene located on chromosome 4q11-21 encodes the c-KIT receptor, whose ligand is a stem cell factor (SCF, blue-grey factor, kit ligand, mast cell growth factor). The receptor has tyrosine protein kinase activity, and the combination of the ligand SCF causes the autophosphorylation of c-KIT and its association with substrates such as phosphatidylinositol 3-kinase (PI3K). Tyrosine phosphorylation by protein tyrosine kinase is particularly important in cell signaling, and can mediate signals of major cell processes (such as proliferation, survival, differentiation, apoptosis, adhesion, invasiveness and migration).
[0005] The receptor tyrosine kinase c-KIT gene is essential for mast cell growth, survival, differentiation and homeostasis. Activating mutations or overexpression of the c-KIT gene enhance the ability of the c-KIT receptor to initiate intracellular pathways that lead to abnormal mast cell proliferation.
[0006] Mastocytosis is a rare disorder characterized by abnormal accumulation of mast cells (MC) in the skin, bone marrow and internal organs (e.g., liver, spleen, gastrointestinal tract and lymph nodes). Cases that begin during adulthood are often chronic and involve the bone marrow in addition to the skin, but during childhood, the disease is usually marked by skin manifestations, without internal organ involvement, and can usually be relieved during adolescence. In most adult patients, mastocytosis tends to persist and may progress to more advanced categories in a few patients. Depending on the patient's symptoms and overall performance, mastocytosis can be classified into specific types. Types of mastocytosis include cutaneous mastocytosis (e.g., maculopapular cutaneous mastocytosis, mastocytoma, and diffuse cutaneous mastocytosis) and systemic mastocytosis (e.g., indolent systemic mastocytosis (ISM), systemic smoldering mastocytosis (SSM), systemic mastocytosis with clonal hematologic non-mast cell lineage disease (SM-AHN), aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and mast cell sarcoma). In rare cases, aggressive neoplastic mast cell outgrowths lead to end-organ failure, whereby patients have a significantly shortened lifespan and require cytoreductive therapy. Pathological accumulation of neoplastic mast cells caused by oncogenic mutations of c-KIT has been found to be the cause of systemic mastocytosis. The major activating KIT mutation is an aspartate to valine substitution at residue 816 (KIT D816V). Patients with systemic mastocytosis, whose mast cells often contain activated D816Vc-KIT mutations, may be inert to aggressive diseases, and they may experience symptoms associated with mast cell mediator release. Inert systemic mastocytosis with repeated allergic reactions or vascular collapse in the absence of skin lesions is an inert systemic mastocytosis of a specific subtype, and this clonal MC activation disorder represents a large part of all mast cell activation syndromes. V560G KIT mutations are extremely rare in patients with systemic mastocytosis, and their biological and prognostic effects are unclear. Currently, most tyrosine kinase inhibitors only show moderate efficacy in late disease states, with significant side effects. In addition, some aggressive KIT mutations (including KIT D816V mutations) are resistant to classic ATP competitive KIT inhibitors (such as imatinib, sunitinib, sorafenib and regorafenib). Midostaurin, an inhibitor of c-KIT D816V, was recently approved for the treatment of SM in 2017.
[0007] Although the c-KIT D816V mutation is a primary c-KIT mutation reported as a driver of systemic mastocytosis (SM), secondary c-KIT mutations that confer resistance to certain c-KIT inhibitors ("secondary resistance c-KIT mutations") have also been reported in mastocytosis patients, including, for example, Y269C, Y503_F504insAY, V560D or K642E point mutations, in-frame deletions or insertions, or missense mutations of the c-KIT gene.
[0008] Activating mutations or overexpression of the c-KIT gene are associated with neoplastic mast cell proliferation. Given the complex functions of c-KIT and the potential use of c-KIT inhibitors in the treatment of drug-resistant systemic mastocytosis, there is a need for inhibitors and therapeutic treatments with favorable therapeutic properties. Summary of the invention
[0009] The present disclosure relates in part to the use of a c-KIT inhibitor, e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (Compound A), and a MAPKAP pathway inhibitor, e.g., a MEK inhibitor such as trametinib, or an ERK inhibitor such as uritinib, or a RAF inhibitor such as LY3009120, for inducing apoptosis in mastocytosis cells.
[0010] Also provided in the present disclosure is a method of treating mastocytosis in a patient in need thereof, the method comprising administering to the patient: an effective amount of a c-KIT inhibitor, such as 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (such as Compound A described herein); and an effective amount of a mitogen-activated protein kinase inhibitor (MEK inhibitor) and / or an effective amount of an extracellular signal-regulated kinase inhibitor (ERK inhibitor).
[0011] For example, provided herein is a method for treating systemic mastocytosis in a patient in need thereof, the method comprising administering to the patient: an effective amount of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharmaceutically acceptable salt thereof; and an effective amount of a mitogen-activated protein kinase inhibitor (MEK inhibitor) or an ERK inhibitor.
[0012] Also contemplated in the present disclosure are methods of treating mastocytosis in a patient in need thereof, the method comprising administering to the patient: an effective amount of a c-KIT inhibitor; and an effective amount of a RAF inhibitor. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1A Shown are graphical representations of cell proliferation following indicated drug treatment with Compound A compared to vehicle control in HMC1.1 V560G (left panel) and HMC1.2 V560G / D816V (right panel) cell lines.
[0014] Figure 1B Shown are graphical representations of cell proliferation following indicated drug treatment with Compound B compared to vehicle control in HMC1.1 V560G (left panel) and HMC1.2 V560G / D816V (right panel) cell lines.
[0015] Figure 2A Shown is a graphical representation of caspase activity after the indicated various treatments with Compound A and Trametinib in the HMC1.2 V560G / D816V cell line.
[0016] Figure 2B A synergy matrix plot based on the combination indexing approach is provided for various treatments with Compound A and trametinib in the HMC1.2 V560G / D816V cell line.
[0017] Figure 2C A combination index plot is provided for the combination of Compound A and the MEK inhibitor trametinib.
[0018] Figure 3A Shown is a graphical representation of caspase activity after the indicated various treatments with Compound B and Trametinib in the HMC1.2 V560G / D816V cell line.
[0019] Figure 3B A synergy matrix plot based on the combination indexing approach is provided for various treatments with Compound B and trametinib in the HMC1.2 V560G / D816V cell line.
[0020] Figure 3C A combination index plot is provided for the combination of Compound B and the MEK inhibitor trametinib.
[0021] Figure 4A Shown is a graphical representation of caspase activity after the indicated various treatments with Compound A and binimetinib in the HMC1.2 V560G / D816V cell line.
[0022] Figure 4B A synergy matrix plot based on the combination indexing approach is provided for various treatments with Compound A and binimetinib in the HMC1.2 V560G / D816V cell line.
[0023] Figure 4C A combination index graph is provided for the combination of Compound A and the MEK inhibitor binimetinib.
[0024] Figure 5A Shown is a graphical representation of caspase activity after the indicated various treatments with Compound B and binimetinib in the HMC1.2 V560G / D816V cell line.
[0025] Figure 5B A synergy matrix plot based on the combination indexing approach is provided for various treatments with Compound B and binimetinib in the HMC1.2 V560G / D816V cell line.
[0026] Figure 5C A combination index plot is provided for the combination of Compound B with the MEK inhibitor binimetinib.
[0027] Fig. 6A Shown is a graphical representation of caspase activity after the indicated various treatments with Compound A and cobimetinib in the HMC1.2 V560G / D816V cell line.
[0028] Figure 6B A synergy matrix plot based on the combination indexing approach is provided for various treatments with Compound A and cobimetinib in the HMC1.2 V560G / D816V cell line.
[0029] Figure 6C A combination index plot is provided for the combination of Compound A and the MEK inhibitor cobimetinib.
[0030] Fig. 7A Shown is a graphical representation of caspase activity after the indicated various treatments with Compound B and cobimetinib in the HMC1.2 V560G / D816V cell line.
[0031] Figure 7B A synergy matrix plot based on the combination indexing approach is provided for various treatments with Compound B and cobimetinib in the HMC1.2 V560G / D816V cell line.
[0032] Figure 7C A combination index map is provided for the combination of Compound B and the MEK inhibitor cobimetinib.
[0033] Fig. 8A Shown is a graphical representation of caspase activity after the indicated various treatments with Compound A and the ERK inhibitor Uritinib in the HMC1.2 V560G / D816V cell line.
[0034] Figure 8BA synergy matrix based on the combination indexing approach is provided for various treatments with Compound A and the ERK inhibitor Uritinib in the HMC1.2 V560G / D816V cell line.
[0035] Figure 8C A combination index graph is provided for the combination of Compound A and the ERK inhibitor Uritinib.
[0036] Fig. 9A Shown is the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent trametinib, and a combination of Compound A and the MEK inhibitor trametinib in HMC1.2 V560G / D816V cells.
[0037] Fig. 9B Shown is a graphic representation of the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent trametinib, and a combination of Compound A and the MEK inhibitor trametinib in HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony outgrowth.
[0038] Fig. 10A Shown is the inhibition of colony outgrowth following treatment with single-agent Compound B, single-agent trametinib, and a combination of Compound B and the MEK inhibitor trametinib in HMC1.2 V560G / D816V cells.
[0039] Fig. 10B Shown is a graphic representation of the inhibition of colony outgrowth following treatment with single-agent Compound B, single-agent trametinib, and a combination of Compound B and the MEK inhibitor trametinib in HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony outgrowth.
[0040] Fig.11A Shown is the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent bimetinib, and a combination of Compound A and the MEK inhibitor bimetinib in HMC1.2 V560G / D816V cells.
[0041] Fig. 11B Shown is a graphic representation of the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent bimetinib, and a combination of Compound A and the MEK inhibitor bimetinib in HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony outgrowth.
[0042] Fig. 12A Shown is the inhibition of colony outgrowth following treatment with single-agent Compound B, single-agent bimetinib, and a combination of Compound B and the MEK inhibitor bimetinib in HMC1.2 V560G / D816V cells.
[0043] Fig. 12BShown is a graphic representation of the inhibition of colony outgrowth following treatment with single-agent Compound B, single-agent bimetinib, and a combination of Compound B and the MEK inhibitor bimetinib in HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony outgrowth.
[0044] Fig.13A Shown is the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent cobimetinib, and a combination of Compound A and the MEK inhibitor cobimetinib in HMC1.2 V560G / D816V cells.
[0045] Fig. 13B Shown is a graphical representation of the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent cobimetinib, and a combination of Compound A and the MEK inhibitor cobimetinib in HMC1.2 V560G / D816V cells.
[0046] Fig.14A Shown is the inhibition of colony outgrowth following treatment with single-agent Compound B, single-agent cobimetinib, and a combination of Compound B and the MEK inhibitor cobimetinib in HMC1.2 V560G / D816V cells.
[0047] Fig. 14B Shown is a graphical representation of the inhibition of colony outgrowth following treatment with single-agent Compound B, single-agent cobimetinib, and a combination of Compound B and the MEK inhibitor cobimetinib in HMC1.2 V560G / D816V cells.
[0048] Fig.15A Shown are graphical representations of caspase activity in HMC1.2V560G / D816V cells transfected with empty vector (EV, left panel) or N-ras G12D (right panel) after various treatments with Compound A and Trametinib at 24 hours.
[0049] Fig. 15B Shown are graphical representations of caspase activity in HMC1.2V560G / D816V cells transfected with empty vector (left panel) or N-ras G12D (right panel) after various treatments with Compound A and Trametinib at 48 hours.
[0050] Fig.16A Shown are graphical representations of caspase activity in HMC1.2V560G / D816V cells transfected with empty vector (EV, left panel) or N-ras G12D (right panel) after various treatments with Compound A and cobimetinib at 24 hours.
[0051] Fig. 16BShown are graphical representations of caspase activity in HMC1.2V560G / D816V cells transfected with empty vector (left panel) or N-ras G12D (right panel) after various treatments with Compound A and cobimetinib at 48 hours.
[0052] Fig.17A Shown is the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent trametinib, and a combination of Compound A and the MEK inhibitor trametinib in empty vector (EV)-transfected HMC1.2 V560G / D816V cells.
[0053] Fig. 17B Shown is a graphic representation of the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent trametinib, and a combination of Compound A and the MEK inhibitor trametinib in empty vector (EV)-transfected HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony outgrowth.
[0054] Fig. 17C Shown is the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent trametinib, and a combination of Compound A and the MEK inhibitor trametinib in N-ras G12D-transfected HMC1.2 V560G / D816V cells.
[0055] Fig.17D Shown is a graphic representation of the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent trametinib, and a combination of Compound 1 and the MEK inhibitor trametinib in N-ras G12D-transfected HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony outgrowth.
[0056] Fig.18A Shown is the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent cobimetinib, and a combination of Compound A and the MEK inhibitor cobimetinib in empty vector (EV)-transfected HMC1.2 V560G / D816V cells.
[0057] Fig.18B Shown is a graphic representation of the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent Cobimetinib, and a combination of Compound A and the MEK inhibitor Cobimetinib in empty vector (EV)-transfected HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony outgrowth.
[0058] Fig.18C Shown is the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent cobimetinib, and a combination of Compound A and the MEK inhibitor cobimetinib in N-ras G12D-transfected HMC1.2 V560G / D816V cells.
[0059] Fig.18D Shown is a graphic representation of the inhibition of colony outgrowth following treatment with single-agent Compound A, single-agent cobimetinib, and a combination of Compound A and the MEK inhibitor cobimetinib in N-ras G12D-transfected HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony outgrowth. DETAILED DESCRIPTION
[0060] It was found that the combination of a c-KIT inhibitor (e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (Compound A)) and a MAPKAP pathway inhibitor (e.g., MEK inhibitor trametinib, or ERK inhibitor uritinib, or RAF inhibitor LY3009120) unexpectedly synergizes to induce apoptosis of mastocytosis cells, as demonstrated in the accompanying Examples. In addition, the combination therapy methods disclosed herein have a cytocidal effect rather than just a cytostatic effect.
[0061] Without wishing to be bound by any particular theory, it is believed that many c-KIT inhibitors only inhibit certain mutant forms of c-KIT and do not effectively inhibit the c-KIT D816V mutation that causes SM. The present disclosure provides methods for treating c-KIT-mediated mastocytosis by inhibiting both c-KIT and MEK using a c-KIT inhibitor in combination with a MAPKAP pathway inhibitor. In a specific embodiment, the c-KIT inhibitor disclosed herein is Compound A or a pharmaceutically acceptable salt thereof, Compound B or a pharmaceutically acceptable salt thereof, midostaurin or a pharmaceutically acceptable salt thereof, BLU-285 or a pharmaceutically acceptable salt thereof, PLX9486 or a pharmaceutically acceptable salt thereof, or crenolanib or a pharmaceutically acceptable salt thereof. Surprisingly, c-KIT inhibitors (e.g., Compound A and Compound B (and pharmaceutically acceptable salts thereof)) synergize with MEK, ERK or RAF inhibitors to inhibit proliferation and induce apoptosis of mastocytosis cells.
[0062] Thus, in certain embodiments, the disclosure provides methods for inducing cytocidal mast cell killing, inducing apoptosis of mast cells, inhibiting growth or proliferation of mast cells, inhibiting mast cell mediator release, reducing the amount of mast cells accumulated in a tissue or organ, reducing the volume of mastocytosis-associated tumors (such as mast cell leukemia or mast cell sarcoma), and / or inhibiting mast cell regrowth by contacting mast cells (e.g., mast cells comprising c-KIT mutations) with a c-KIT inhibitor and a MAPKAP pathway inhibitor. In various embodiments, the mast cells are contacted in vitro, in vivo, or ex vivo. In specific embodiments, the c-KIT inhibitor disclosed herein is Compound A or a pharmaceutically acceptable salt thereof, Compound B or a pharmaceutically acceptable salt thereof, midostaurin or a pharmaceutically acceptable salt thereof, BLU-285 or a pharmaceutically acceptable salt thereof, PLX9486 or a pharmaceutically acceptable salt thereof, or crenolanib or a pharmaceutically acceptable salt thereof; and the MEK inhibitor disclosed herein is trametinib, cobimetinib, selumetinib or bimetinib; ERK inhibitors include but are not limited to uritinib, SCH772984, LY3214996, ravoxertinib and VX-11e; and RAF inhibitors include but are not limited to LY3009120, vemurafenib or dabrafenib.
[0063] In certain embodiments, the present disclosure includes methods for treating a subject with mastocytosis, mast cell leukemia, or acute myeloid leukemia, the methods comprising administering to the subject an effective amount of: (i) a KIT inhibitor, such as 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharmaceutically acceptable salt thereof, or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea or a pharmaceutically acceptable salt thereof; and (ii) a MAPKAP kinase inhibitor, such as trametinib, bimetinib, uritinib. In specific embodiments of any of the methods disclosed herein, the mastocytosis is systemic mastocytosis caused by a D816V mutation in the c-KIT gene in mast cells.
[0064] definition
[0065] As used herein, "Compounds A and B" refer to 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea, and 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, respectively. Pharmaceutically acceptable salts, tautomers, hydrates and solvates of Compounds A and B are also encompassed in the present disclosure. The structures of Compounds A and B are shown below:
[0066]
[0067] 1-[4-Bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (Compound A)
[0068]
[0069] 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea (Compound B)
[0070] Methods for preparing Compound A and Compound B are disclosed in US Pat. No. 8,461,179 B1, the contents of which are incorporated herein by reference.
[0071] Illustrative methods and materials are described herein. In the specification and the appended claims, unless the context clearly indicates otherwise, the singular also includes the plural. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
[0072] Throughout this disclosure, various patents, patent applications and publications are cited. The disclosures of these patents, patent applications and publications are incorporated herein by reference in their entirety to more fully describe the state of the art known to those skilled in the art as of the date of this disclosure. In the event of any inconsistency between a patent, patent application and publication and this disclosure, this disclosure shall prevail.
[0073] For convenience, certain terms used in the specification, examples and claims are collected here. Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by ordinary technicians in the field to which this disclosure belongs. Unless otherwise indicated, the initial definition provided for a group or term provided in this disclosure applies to the group or term throughout this disclosure, either alone or as part of another group.
[0074] "Pharmaceutically acceptable carriers, diluents or excipients" include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the United States Food and Drug Administration for use in humans or livestock.
[0075] "Pharmaceutically acceptable salts" include acid addition salts.
[0076] "Pharmaceutically acceptable acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed from inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, decanoic acid, hexanoic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2- Hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, etc.
[0077] "Pharmaceutical composition" refers to a formulation of a compound described herein (e.g., Compound A or a pharmaceutically acceptable salt thereof) and a medium generally accepted in the art for delivering the biologically active compound to a mammal (e.g., a human). Therefore, such a medium includes all pharmaceutically acceptable carriers, diluents, or excipients.
[0078] "MAPKAP pathway inhibitors" are inhibitors of the MAP kinase signaling pathway. Inhibitors of this pathway include RAS inhibitors, RAF inhibitors (e.g., vemurafenib, dabrafenib, LY3009120), MEK inhibitors (e.g., trametinib, bimetinib, cobimetinib) and ERK inhibitors (e.g., uritinib).
[0079] Subjects or patients "in need of treatment with a combination therapy of the present disclosure (e.g., a combination of a c-KIT inhibitor and a MAPKAP pathway inhibitor)" include subjects with diseases and / or conditions that can be treated with the combinations disclosed herein to achieve a beneficial therapeutic outcome (e.g., mastocytosis, mast cell leukemia, or acute myeloid leukemia). Beneficial outcomes of treating mastocytosis may include complete response, partial response, clinical improvement, or stable disease, as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121:2393-401). In certain embodiments, the subject in need of treatment has cutaneous mastocytosis (e.g., maculopapular cutaneous mastocytosis, mastocytoma, and diffuse cutaneous mastocytosis) and systemic mastocytosis (e.g., indolent systemic mastocytosis, systemic smoldering mastocytosis, systemic mastocytosis with clonal hematological non-mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma). In specific embodiments, the subject is a mammal, such as a human or other mammal.
[0080] When used in combination with the compounds disclosed herein or other therapeutic agents, the term "effective amount" refers to the amount of a therapeutic agent (e.g., Compound A or a MAPKAP pathway inhibitor) that can be used to treat or prevent a disease or disorder, either alone or in combination. The effective amount of a therapeutic agent used in a combination therapy is the amount of each therapeutic agent that can be used to treat or prevent a disease or disorder when used in a combination therapy, even if the amount of one or two of the therapeutic agents is ineffective for treating or preventing the disease or disorder in the absence of the other therapeutic agents. In certain embodiments, the effective amount is an amount that results in inducing cytocidal mast cell killing, inducing apoptosis of mast cells, reducing the amount of mast cells accumulated in tissues or organs, alleviating symptoms of mastocytosis, inhibiting mast cell mediator release, inhibiting mast cell growth, and / or inducing regression of mastocytosis, wherein the mast cells possess an activating mutation in c-KIT kinase, including an activating c-KIT D816V mutation. An "effective amount" can vary according to the mode of administration, the specific site of the disease or disorder, and the age, weight, and overall health of the subject. The amount of compound administered will depend on the extent, severity and type of the disease or condition, the amount of therapy required and the release characteristics of the one or more pharmaceutical formulations. It will also depend on the subject's health, size, weight, age, sex and tolerance to the drug. Generally, the compound is administered for a sufficient period of time to achieve the desired therapeutic effect.
[0081] The terms "treatment", "treat" and "treating" are intended to include a full range of interventions for the treated patient (e.g., a patient with mastocytosis or acute myeloid leukemia (AML)). Treatment may be a cure, an improvement, or at least a partial alleviation of the disorder. In a particular embodiment, the intention of treatment is to induce cytocidal mast cell killing, induce apoptosis of mast cells, reduce the amount of mast cells accumulated in tissues or organs, alleviate the symptoms of mastocytosis, inhibit mast cell mediator release, inhibit the growth of mast cells, and / or induce mastocytosis regression in the treated subject. In certain embodiments, even if mastocytosis is not actually eliminated, treatment with the combination therapy disclosed herein also alleviates, slows down or reverses the symptoms of one or more mastocytosis and / or induces the regression of mastocytosis. In some embodiments, treatment includes complete elimination of a disease or disorder, such as mastocytosis or AML. In other embodiments, treatment results in a complete response, partial response, clinical improvement, or stable disease as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121:2393-401).
[0082] As used herein, "mast cells" include mast cells (also called mastocytes) and CD34+ mast cell precursor cells.
[0083] As used herein, "neoplasm" refers to abnormal tissue that grows faster than normal through cell proliferation. Neoplasms show a partial or complete lack of structural organization and functional coordination with normal tissue, and usually form a distinct mass of tissue that may be benign (benign tumor) or malignant (cancer).
[0084] As used herein, "tumor" refers to a mass. This is a term that may refer to a benign (usually harmless) or malignant (cancerous) growth. Malignant growths can originate from solid organs or the bone marrow. The latter are often called liquid tumors. "Tumors" encompass mast cell leukemia and mast cell sarcoma, collectively referred to herein as "mastocytosis tumors."
[0085] In certain embodiments, standard response criteria known in the art can be used to measure the therapeutic effect of treating mastocytosis according to the methods disclosed herein. For example, the "complete remission (CR), partial remission (PR), clinical improvement (CI) or disease stabilization (SD) response criteria" for the effects of quantitative therapy on aggressive systemic mastocytosis, mast cell leukemia and systemic mastocytosis associated with bone marrow neoplasms can be any of those defined by IWG-MRT-ECNM (Gotlib et al., Blood 2013; 121: 2393-401). For example, complete remission (CR) requires all 4 criteria, and the duration of response must be ≥12 weeks, and there is no dense neoplastic mast cell aggregates in the dermis of BM or other biopsies. Serum tryptase level < Peripheral blood count remission was defined as ANC ≥ 1 × 10 9 / L, Hb level ≥11 g / dL, and platelet count ≥100 × 10 9 / L, and complete resolution of palpable hepatosplenomegaly and all biopsy-confirmed or suspected SM-related organ damage (CI findings); in the absence of both CR and progressive disease (PD), partial response (PR)* requires all 3 criteria to be met, and the duration of response must be ≥12 weeks, where: a ≥50% reduction in neoplastic MCs in the bone marrow and / or other extradermal organs at biopsy indicates qualifying SM-related organ damage, and a ≥50% reduction in serum tryptase levels; and resolution of 1 or more biopsy-confirmed or suspected SM-related organ damage (one or more CI findings); clinical improvement (CI) is in the absence of both CR / PR and assigned or progressive disease (PD), and one or more non-hematologic and / or hematologic response criteria need to be met (see Table 3). Stable disease (SD) does not meet the criteria for CR, PR, CI, or PD.
[0086] Criteria for defining response include: (1) Only disease-related grade ≥2 organ damage can be evaluated as a primary endpoint in clinical trials. (2) Response definitions of CR, PR, SD, PD, and loss of response (LOR) should apply only to these grade ≥2 organ damage findings in the trial context. (3) Disease status at the time a patient is removed from the study is related only to the updated status of one or more initial grade ≥2 organ damage findings. (4) In patients with an exacerbation of baseline grade ≥2 organ damage, exclusion of drug-related toxicity and / or other clinical issues (e.g., gastrointestinal bleeding in the setting of worsening anemia / transfusion dependence) should be performed before assigning the designation PD or LOR.
[0087] In certain embodiments, the therapeutic efficacy of treating AML according to the methods disclosed herein can be measured using standard response criteria known in the art. For example, a "response criteria for AML treatment" used to quantify the efficacy of a therapy for AML can be any of those defined below, including complete remission (CR) without minimal residual disease (MRD), complete remission (CR ... MRD- ), complete remission (CR), CR with incomplete hematological recovery (CR i ), morphologic leukemia-free state (MLFS), partial response (PR), stable disease (SD), or progressive disease (PD), as defined by Blood. 2017 Jan 26; 129(4):424–447, and summarized as complete response without minimal residual disease (CR MRD- ): CR with negativity for genetic markers by RT-qPCR if before study treatment, or CR with negativity by MFC; Complete remission (CR): bone marrow blasts <5%; absence of circulating blasts and blasts with Auer bodies; absence of extramedullary disease; absolute neutrophil count (ANC) ≥1.0×10 9 / L (1000 / μL); platelet count ≥100×10 9 / L (100000 / μL); CR with incomplete hematologic recovery (CR i ): Except for residual neutropenia (<1.0×10 9 / L [1000 / μL]) or thrombocytopenia (<100×10 9 / L [100000 / μL]); morphological leukemia-free status (MLFS): bone marrow blasts <5%; absence of blasts with Auer bodies; absence of extramedullary disease; no hematologic recovery required; partial remission (PR): all hematologic criteria for CR; reduction in bone marrow blast percentage to 5% to 25%; and a reduction of at least 50% in the pretreatment bone marrow blast percentage.
[0088] "Combination therapy" is a treatment that includes administering to a patient two or more of the following therapeutic agents: for example, a c-KIT inhibitor (such as Compound A or a pharmaceutically acceptable salt thereof, midostaurin, BLU-285, PLX9486, or crenolanib) and a MAPKAP pathway inhibitor (including but not limited to trametinib, cobimetinib, selumetinib, bimetinib, uritinib, LY3009120). The two or more therapeutic agents can be delivered simultaneously, for example, in separate pharmaceutical compositions or in the same pharmaceutical composition, or they can be delivered at different times. For example, they can be delivered in parallel or in overlapping time periods, and / or one therapeutic agent can be delivered before or after the other one or more therapeutic agents. Treatment with a combination of a KIT inhibitor (such as Compound A) and a MAPKAP pathway inhibitor optionally includes treatment with either agent before or after the concurrent treatment period with the two agents. However, it can be expected that over a period of time, an effective amount of two or more therapeutic agents will be present in the patient.
[0089] Treatment
[0090] In one embodiment, the present disclosure provides a method for treating or preventing mastocytosis (optionally c-KIT-mediated mastocytosis, such as systemic mastocytosis (SM)), the method comprising providing or administering to a subject in need thereof an effective amount of a c-KIT inhibitor and an effective amount of a MAPKAP pathway inhibitor (e.g., trametinib, cobimetinib, selumetinib, bimetinib, uritinib, or LY3009120) in combination. In one embodiment, the present disclosure provides a method for treating or preventing mastocytosis (optionally c-KIT-mediated mastocytosis, such as systemic mastocytosis (SM)), the method comprising providing or administering to a subject in need thereof an effective amount of Compound A (or a pharmaceutically acceptable salt thereof) or Compound B (or a pharmaceutically acceptable salt thereof) and an effective amount of a MAPKAP pathway inhibitor (e.g., trametinib, cobimetinib, selumetinib, bimetinib, uritinib, or LY3009120) in combination. In a related embodiment, the present disclosure provides a method for treating or preventing a mastocytosis tumor (optionally a c-KIT-mediated mastocytosis tumor, such as a mast cell leukemia or mast cell sarcoma), the method comprising providing or administering to a subject in need thereof an effective amount of a c-KIT inhibitor in combination with an effective amount of a MAPKAP pathway inhibitor (e.g., trametinib, cobimetinib, selumetinib, bimetinib, uritinib, or LY3009120). In a related embodiment, the present disclosure provides a method for treating or preventing a mastocytosis tumor (optionally a c-KIT-mediated mastocytosis tumor, such as a mast cell leukemia or mast cell sarcoma), the method comprising providing or administering to a subject in need thereof an effective amount of Compound A (or a pharmaceutically acceptable salt thereof) or Compound B (or a pharmaceutically acceptable salt thereof) in combination with an effective amount of a MAPKAP pathway inhibitor (e.g., trametinib, cobimetinib, selumetinib, bimetinib, uritinib, or LY3009120).
[0091] In another example, the present disclosure provides a method for treating mastocytosis in a patient in need thereof, the method comprising administering to the patient: an effective amount of a c-KIT inhibitor; and an effective amount of one or more MAPKAP pathway inhibitors. Such MAPKAP pathway inhibitors can be selected from the group consisting of: rapidly accelerated fibrosarcoma (RAF) kinase inhibitors, mitogen-activated protein kinase inhibitors (MEK inhibitors), and extracellular signal-regulated kinase inhibitors (ERK inhibitors).
[0092] In one embodiment of the disclosed method, the mastocytosis has a c-KIT mutation. In some embodiments, the c-KIT mutation is an activating mutation.
[0093] In another embodiment, mastocytosis may comprise mast cells having a primary mutation in exon 17 of the c-KIT gene. In some embodiments, the primary mutation is a c-KIT D816 mutation. In some embodiments, the primary mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and del419. In some embodiments, the primary mutation is D816V.
[0094] Mastocytosis may also include mast cells with secondary c-KIT mutations. In some embodiments, the secondary c-KIT mutation is in one of exons 9, 11, 13, or 17. In some embodiments, the secondary c-KIT mutation is one of a Y269C, Y503_F504insAY, V560D, or K642E mutation.
[0095] Such disclosed methods may also include determining whether mastocytosis has a c-KIT primary mutation. For example, the method further includes determining whether mastocytosis has a c-KIT secondary mutation. In some embodiments, determining whether mastocytosis has a c-KIT primary or secondary mutation comprises identifying a mutation in DNA extracted from a tumor sample. In yet another embodiment, determining whether mastocytosis has a c-KIT primary or secondary mutation comprises identifying a mutation in circulating tumor DNA or identifying a mutation in circulating peripheral blood leukocytes.
[0096] Mastocytosis can be systemic mastocytosis. In some embodiments, systemic mastocytosis is selected from the group consisting of: indolent systemic mastocytosis, systemic smoldering mastocytosis, systemic mastocytosis with clonal hematological non-mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma. In some embodiments, mastocytosis is indolent systemic mastocytosis, optionally indolent systemic mastocytosis with recurrent allergic reactions or vascular collapse in the absence of skin lesions. In some embodiments, mastocytosis is systemic smoldering mastocytosis.
[0097] In some embodiments, mastocytosis is systemic mastocytosis with clonal hematological non-mast cell lineage disease. In some embodiments, mastocytosis is aggressive systemic mastocytosis. In some embodiments, mastocytosis is mast cell leukemia or mast cell sarcoma. In some embodiments, mastocytosis is cutaneous mastocytosis. In some embodiments, mastocytosis is selected from the group consisting of maculopapular cutaneous mastocytosis, mastocytoma, or diffuse cutaneous mastocytosis.
[0098] In this disclosed method, the c-KIT inhibitor can be selected from the group consisting of: 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharmaceutically acceptable salt thereof, midostaurin or a pharmaceutically acceptable salt thereof, imatinib mesylate, sunitinib malate, midostaurin, regorafenib, crenolanib, PTX9486, or BLU-285 (avapritinib) or a pharmaceutically acceptable salt thereof.
[0099] In addition, the MEK inhibitor can be selected from the group consisting of: trametinib, selumetinib, cobimetinib and bimetinib. In some embodiments, the MEK inhibitor is bimetinib. In some embodiments, the MEK inhibitor is trametinib. In some embodiments, the ERK inhibitor is selected from the group consisting of: uritinib, SCH772984 and LY3214996. In some embodiments, the c-KIT inhibitor and the MEK and / or ERK inhibitor are administered substantially in parallel or sequentially.
[0100] The method may also include administering another cancer-targeted therapeutic agent, a cancer-targeted biological immune checkpoint inhibitor, or a chemotherapeutic agent.
[0101] Additionally, administration of an effective amount of a c-KIT inhibitor; and an effective amount of a mitogen-activated protein kinase inhibitor (MEK inhibitor), and / or an effective amount of an extracellular signal-regulated kinase inhibitor (ERK inhibitor) for two weeks or longer in accordance with the contemplated methods may result in a patient having at least a partial remission.
[0102] Also provided is a method of treating systemic mastocytosis in a patient in need thereof, the method comprising administering to the patient: an effective amount of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharmaceutically acceptable salt thereof; and an effective amount of a MAPKAP pathway inhibitor. In this disclosed method, the MAPKAP pathway inhibitor is selected from the group consisting of a rapidly accelerated fibrosarcoma (RAF) kinase inhibitor, a mitogen-activated protein kinase inhibitor (MEK inhibitor), and an extracellular signal-regulated kinase inhibitor (ERK inhibitor).
[0103] In one embodiment, systemic mastocytosis may have a c-KIT mutation. For example, the mutation may be a c-KIT D816 mutation. In some embodiments, the mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and del419. In some embodiments, the mutation is one of: A553D, C433Y, D419Y, D572A, D816F, D816H, D816I, D816V, D816Y, D820G, del419, dup (501-502), E839K, F522C, I817V, InsFF419, InsV815-I816, K509I, N822I, R815K, T417V, V560G, V559I or Y418Y. In some embodiments, the mutation is D816V.
[0104] Additionally, the mastocytosis may have an additional c-KIT mutation, the additional c-KIT mutation being one of the Y269C, Y503_F504insAY, V560D, or K642E mutations.
[0105] In this disclosed method, the MEK inhibitor can be selected from the group consisting of: trametinib, selumetinib, cobimetinib and bimetinib. In some embodiments, the MEK inhibitor is bimetinib. In some embodiments, the MEK inhibitor is trametinib. The ERK inhibitor can be selected from the group consisting of: uritinib, SCH772984 and LY3214996.
[0106] The present disclosure further provides methods of treating mastocytosis in a patient in need thereof, the method comprising administering to the patient: an effective amount of a c-KIT inhibitor; and an effective amount of a RAF inhibitor.
[0107] In this disclosed method, the RAF inhibitor can be a pan-RAF or B-RAF inhibitor, including vemurafenib, dabrafenib and LY3009120. In addition, the c-KIT inhibitor can be 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharmaceutically acceptable salt thereof.
[0108] In certain embodiments of the methods disclosed herein, methods of treating mastocytosis or mastocytosis tumors are included, the methods comprising: inducing cytocidal mast cell killing, inducing apoptosis of mast cells, reducing the amount of mast cells accumulated in tissues or organs, alleviating symptoms of mastocytosis, inhibiting mast cell mediator release, inhibiting mast cell growth, and / or inducing mastocytosis regression, wherein the mast cells possess one or more activating mutations in c-KIT kinase, e.g., an activating c-KIT D816V mutation. In certain embodiments, the methods encompass methods for eliminating mastocytosis (e.g., mastocytosis tumors) in a subject. In some embodiments, treatment results in a complete response, a partial response, clinical improvement, or stable disease, as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121: 2393-401).
[0109] In another related embodiment, the present disclosure provides a method for treating or preventing acute myeloid leukemia (AML), optionally c-KIT-mediated (AML), comprising administering to a subject in need thereof an effective amount of a c-KIT inhibitor in combination with an effective amount of a MAPKAP pathway inhibitor (e.g., trametinib, cobimetinib, selumetinib, bimetinib, uritinib, or LY3009120). In a related embodiment, the present disclosure provides a method for treating or preventing acute myeloid leukemia (AML), optionally c-KIT-mediated (AML), comprising administering to a subject in need thereof an effective amount of Compound A (or a pharmaceutically acceptable salt thereof) or Compound B (or a pharmaceutically acceptable salt thereof) in combination with an effective amount of a MAPKAP pathway inhibitor (e.g., trametinib, cobimetinib, selumetinib, bimetinib, uritinib, or LY3009120).
[0110] Where the methods described herein involve treatment with Compound A or a pharmaceutically acceptable salt thereof, or with Compound B or a pharmaceutically acceptable salt thereof, it means that only one of Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof is required. However, it should be understood that these methods also encompass administration of both Compound A or a pharmaceutically acceptable salt thereof, and Compound B or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor to a patient. The methods described herein also encompass administration of Compound A and a MAPKAP pathway inhibitor to a subject, followed by Compound A being metabolized in vivo to Compound B, and the in vivo mixture of Compound A and Compound B in combination with a MAPKAP pathway inhibitor effectively treating the subject.
[0111] Specific embodiments of the disclosed methods and compositions are implemented using the following compounds: a combination of Compound A, or a pharmaceutically acceptable salt thereof, and trametinib; a combination of Compound A, or a pharmaceutically acceptable salt thereof, and selumetinib; a combination of Compound A, or a pharmaceutically acceptable salt thereof, and cobimetinib; or a combination of Compound A, or a pharmaceutically acceptable salt thereof, and bimetinib.
[0112] In one embodiment, Compound A or a pharmaceutically acceptable salt thereof and a MEK inhibitor (e.g., trametinib or bimetinib) are administered to a subject with c-KIT-mediated mastocytosis. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and a MEK inhibitor (e.g., trametinib or bimetinib) are administered to a subject with c-KIT-mediated mastocytosis.
[0113] In a related embodiment, Compound A, or a pharmaceutically acceptable salt thereof, and a MEK inhibitor (e.g., trametinib or bimetinib) are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or mast cell sarcoma, wherein the tumor growth or tumor progression of mastocytosis is caused by a primary activating c-KIT mutation (e.g., KIT D816V mutation). In another embodiment, Compound B, or a pharmaceutically acceptable salt thereof, and a MEK inhibitor (e.g., trametinib or bimetinib) are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or mast cell sarcoma, wherein the tumor growth or tumor progression of mastocytosis is caused by a primary activating c-KIT mutation (e.g., KIT D816V mutation). In certain embodiments, Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof, and a MEK inhibitor (e.g., trametinib or binimetinib) are administered to a patient with AML, optionally wherein the AML is caused by a primary activating c-KIT mutation (e.g., a c-KIT exon 8 activating mutation, or a c-KIT exon 17 mutation, including but not limited to a mutation at D816 or at N822 (Journal of Clinical Oncology 2006 24:24, 3904-3911)).
[0114] Specific embodiments of the disclosed methods and compositions are implemented using the following compounds: a combination of Compound A or a pharmaceutically acceptable salt thereof and uritinib; a combination of Compound A or a pharmaceutically acceptable salt thereof and SCH772984; a combination of Compound A or a pharmaceutically acceptable salt thereof and LY3214996; a combination of Compound A or a pharmaceutically acceptable salt thereof and lavotinib; or a combination of Compound A or a pharmaceutically acceptable salt thereof and VX-11.
[0115] In one embodiment, Compound A or a pharmaceutically acceptable salt thereof and an ERK inhibitor (e.g., Uritinib) are administered to a subject with c-KIT-mediated mastocytosis. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and an ERK inhibitor (e.g., Uritinib) are administered to a subject with c-KIT-mediated mastocytosis.
[0116] In a related embodiment, Compound A, or a pharmaceutically acceptable salt thereof, and an ERK inhibitor (e.g., Uritinib) are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or mast cell sarcoma, wherein the tumor growth or tumor progression of mastocytosis is caused by a primary activating c-KIT mutation (e.g., KIT D816V mutation). In another embodiment, Compound B, or a pharmaceutically acceptable salt thereof, and an ERK inhibitor (e.g., Uritinib) are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or mast cell sarcoma, wherein the tumor growth or tumor progression of mastocytosis is caused by a primary activating c-KIT mutation (e.g., KIT D816V mutation). In certain embodiments, Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof, and an ERK inhibitor (e.g., uritinib) are administered to a patient with AML, optionally wherein the AML is caused by a primary activating c-KIT mutation (e.g., a c-KIT exon 8 activating mutation, or a c-KIT exon 17 mutation, including but not limited to a mutation at D816 or at N822 (Journal of Clinical Oncology 2006 24:24, 3904-3911)).
[0117] Particular embodiments of the disclosed methods and compositions are implemented using the following compounds: a combination of Compound A, or a pharmaceutically acceptable salt thereof, and LY3009120; a combination of Compound A, or a pharmaceutically acceptable salt thereof, and dabrafenib; or a combination of Compound A, or a pharmaceutically acceptable salt thereof, and vemurafenib.
[0118] In one embodiment, Compound A or a pharmaceutically acceptable salt thereof and a RAF inhibitor (e.g., LY3009120, dabrafenib or vemurafenib) are administered to a subject with c-KIT-mediated mastocytosis. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and a RAF inhibitor (e.g., LY3009120, dabrafenib or vemurafenib) are administered to a subject with c-KIT-mediated mastocytosis.
[0119] In a related embodiment, Compound A, or a pharmaceutically acceptable salt thereof, and a RAF inhibitor (e.g., LY3009120, dabrafenib, or vemurafenib) are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or mast cell sarcoma, wherein the tumor growth or tumor progression of mastocytosis is caused by a primary activating c-KIT mutation (e.g., KIT D816V mutation). In another embodiment, Compound B, or a pharmaceutically acceptable salt thereof, and a RAF inhibitor (e.g., LY3009120, dabrafenib, or vemurafenib) are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or mast cell sarcoma, wherein the tumor growth or tumor progression of mastocytosis is caused by a primary activating c-KIT mutation (e.g., KIT D816V mutation). In certain embodiments, Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof, and a RAF inhibitor (e.g., LY3009120, dabrafenib, or vemurafenib) are administered to a patient with AML, optionally wherein the AML is caused by a primary activating c-KIT mutation (e.g., a c-KIT exon 8 activating mutation, or a c-KIT exon 17 mutation, including but not limited to a mutation at D816 or at N822 (Journal of Clinical Oncology 2006 24:24, 3904-3911)).
[0120] Illustrative c-KIT inhibitors that can be used according to the disclosed methods and compositions include, but are not limited to, Compound A or a pharmaceutically acceptable salt thereof, Compound B or a pharmaceutically acceptable salt thereof, midostaurin, BLU-285, PLX9486, and crenolanib. Illustrative MEK inhibitors that can be used according to the disclosed methods and compositions include, but are not limited to, trametinib, selumetinib, cobimetinib, and bimetinib. Illustrative ERK inhibitors that can be used according to the disclosed methods and compositions include, but are not limited to, uritinib, SCH772984, LY3214996, ravoxertinib, and VX-11e. Illustrative RAF inhibitors that can be used according to the disclosed methods and compositions include, but are not limited to, LY3009120, dabrafenib, and vemurafenib.
[0121] Treatment with Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) encompasses administration of Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof, in a time period prior to, after, concurrently with, or overlapping with administration of the MAPKAP pathway inhibitor. It should be understood that the effective amount of any of Compound A, or a pharmaceutically acceptable salt thereof, Compound B, or a pharmaceutically acceptable salt thereof, another c-KIT inhibitor, or a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) when used in a combination disclosed herein may be different than when any of these agents are used alone by themselves for the same purpose (e.g., for the treatment or prevention of mastocytosis or mast cell tumors, such as mast cell leukemia or AML). In certain embodiments, the effective amount of Compound A or a pharmaceutically acceptable salt thereof or the effective amount of Compound B or a pharmaceutically acceptable salt thereof is a lower amount when administered as a combination therapy with a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) than when administered as a monotherapy (e.g., for the treatment or prevention of mastocytosis or mast cell tumors). In certain embodiments, the effective amount of a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) is a lower amount when administered as a combination therapy with Compound A or a pharmaceutically acceptable salt thereof or when administered as a combination therapy with Compound B or a pharmaceutically acceptable salt thereof (e.g., for the treatment or prevention of mastocytosis or mast cell tumors).
[0122] Any method disclosed herein may also include determining that the treated mastocytosis cells, mast cell tumors or AML have one or more c-KIT gene mutations. This determination can be made by conventional methods for determining the presence of gene mutations in biological samples (e.g., bone marrow samples, tissue samples, peripheral blood samples, or plasma samples) obtained from a subject. In addition, this determination can be made by reviewing the test results performed to determine the presence of one or more c-KIT gene mutations in biological samples obtained from a patient. In certain embodiments of any method disclosed herein, the method is performed on a subject in which mastocytosis, mast cell tumors, or AML have been identified as having one or more c-KIT gene mutations. C-KIT gene mutations include, but are not limited to, any of those specifically described herein. In certain embodiments of any method disclosed herein, the method is not performed on a subject in which mastocytosis, mast cell tumors, or AML have been identified as having one or more c-KIT gene mutations.
[0123] In various aspects of any of the methods disclosed herein, treatment with Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) induces cytocidal mast cell killing, induces apoptosis of mast cells, reduces the amount of mast cells accumulated in a tissue or organ, reduces symptoms of mastocytosis, inhibits mast cell mediator release, inhibits mast cell growth, and / or induces regression of mastocytosis, wherein the mast cells possess an activating mutation in c-KIT kinase, including an activating c-KIT D816V mutation. Methods of measuring or determining mast cell apoptosis, the amount of mast cell killing, inhibition of mast cell growth and proliferation, inhibition of mast cell mediator release, peripheral blood mutant KIT allele burden, eradication of mastocytosis and mastocytosis tumors; complete response, partial response, clinical improvement, or stable disease are known in the art and include any of the methods described herein.
[0124] In certain embodiments, treatment with a combination of: a c-KIT inhibitor (e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) results in an increase in the amount of apoptosis of the mastocytosis cells or mast cells, as compared to the amount of apoptosis of the same type of mastocytosis cells or mast cells that are untreated or treated with a MAPKAP pathway inhibitor alone or with a c-KIT inhibitor alone (e.g., Compound A or Compound B). For example, apoptosis may be increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, at least 10-fold, or at least 20-fold. In certain embodiments, the amount of apoptosis is determined by measuring caspase activity in KIT mutant mast cells or mast cell lines, including the HMC1.2 mast cell line that possesses the KIT D816V mutation.
[0125] In certain embodiments, treatment with a combination of: a c-KIT inhibitor (e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) results in a decrease in the accumulation of mast cells in the skin or an internal organ (e.g., liver, spleen, bone marrow, and / or small intestine) as compared to the amount of mast cell accumulation in the same organ in the absence of treatment or treatment with a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) alone or with a c-KIT inhibitor (e.g., midostaurin, BLU-285, Compound A, or Compound B) alone. For example, the amount or number of mast cells accumulated in an organ may be reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[0126] In certain embodiments, treatment with the combination of: a c-KIT inhibitor (e.g., Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, binimetinib, uritinib, or LY3009120) results in a complete response as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121: 2393-401).
[0127] In certain embodiments, treatment with the combination of: a c-KIT inhibitor (e.g., Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, binimetinib, uritinib, or LY3009120) results in a partial response as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121: 2393-401).
[0128] In certain embodiments, treatment with the combination of: a c-KIT inhibitor (e.g., Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, binimetinib, uritinib, or LY3009120) results in clinical improvement as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121: 2393-401).
[0129] In certain embodiments, treatment with the combination of: a c-KIT inhibitor (e.g., Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, binimetinib, uritinib, or LY3009120) results in stable disease as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121: 2393-401).
[0130] In certain embodiments, treatment with a combination of: a c-KIT inhibitor (e.g., Compound A, or a pharmaceutically acceptable salt thereof, or Compound B, or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, binimetinib, uritinib, or LY3009120) results in apoptosis or inhibition of growth of resistant mast cells containing secondary KIT mutations in addition to the KIT D816V primary mutation, wherein the secondary KIT mutations include, but are not limited to, Y269C, Y503_F504insAY, V560D, or K642E point mutations, in-frame deletions or insertions, or missense mutations in the c-KIT gene (Lasho et al., Br J Haematol 173, 153-156).
[0131] In certain embodiments, treatment is performed with a combination of a c-KIT inhibitor (e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) to induce apoptosis or growth inhibition of resistant mastocytosis cells containing mutations (e.g., resistance mutations) in other genes (including any disclosed herein). In certain embodiments, such other gene mutations may include NRas gain-of-function mutations (Haematologica 2011; 96(03):459-463.doi:10.3324 / haematol.2010.031690) or TET2 loss-of-function mutations (Leukemia 2009; 23:900-04; Blood, Dec. 6, 2012; 120(24):4846-49). The presence of mutations in other epigenetic or transcriptional regulators has been detected in SM, including DNMT3A, ASXL1, and CBL in 12%, 12%, and 4% of patients, respectively (PloSone. 2012; 7: e43090). In addition, some patients with mastocytosis also present mutations in the spliceosomal machinery. The spliceosome ensures the correct linear order of exons spliced in the mRNA. Hanssens et al. reported that in a group of 72 patients with mastocytosis, the mutation incidence of SRSF2 was 23.6%, the mutation incidence of SF3B1 was 5.6%, and the mutation incidence of U2AF1 was 2.7% (Haematologica 2014; 99: 830-35). Such mastocytosis with complex genomic drivers may benefit from treatment with a combination of a c-KIT inhibitor and a MEK inhibitor disclosed herein, compared to untreated or treated with a MEK inhibitor (e.g., trametinib) alone or with a c-KIT inhibitor (e.g., Compound A or Compound B) alone. For example, apoptosis may be increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two times, at least three times, at least four times, at least five times, at least 10 times, or at least 20 times. For example, the amount or number of growth of resistant mastocytosis cells may be inhibited by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[0132] In certain embodiments, the resistant mastocytosis cells are rendered resistant to apoptosis-mediated cell death or cytocidal activity by treatment with a c-KIT inhibitor (e.g., Compound A, Compound B, midostaurin, BLU-285, PLX9486, or crenolanib) and / or rendered resistant to apoptosis-mediated cell death or cytocidal activity by treatment with a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) when used as monotherapy.
[0133] In certain embodiments, treatment with a combination of: a c-KIT inhibitor (e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof); and a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) results in eradication of mastocytosis (e.g., a mastocytosis tumor). In certain embodiments, eradication of mastocytosis means that there is no longer any detectable mastocytosis in the patient. In certain embodiments, there is no detectable mastocytosis in the patient at least twelve weeks, at least twenty-four weeks, at least one year, at least two years, or at least five years after initiation of treatment of mastocytosis by a combination therapy disclosed herein. Eradication of mastocytosis can be determined by the criteria of a complete response as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121: 2393-401).
[0134] The present disclosure describes a combination therapy involving the administration of a c-KIT inhibitor (e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof), and a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120). The combination therapy described herein can be used alone by themselves, or in combination with one or more additional therapeutic agents. For example, Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof, and a MAPKAP pathway inhibitor can be administered together with a cancer targeted therapeutic agent, a cancer targeted biological immune checkpoint inhibitor, or a chemotherapeutic agent. In another embodiment, Compound A or Compound B and a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) are administered in the absence of any other therapeutic agent. In the combination therapy, the therapeutic agent can be administered together with another therapeutic agent described herein or administered sequentially therewith.
[0135] Combination therapy can be achieved by the following ways: two or more therapeutic agents are applied, each therapeutic agent is prepared and applied separately; or two or more therapeutic agents are applied in a single preparation. Combination therapy also covers other combinations. Although two or more medicaments in combination therapy can be applied simultaneously, they are not necessarily applied in this way. For example, the application of the first medicament (or a combination of medicaments) can be a few minutes, hours, days or weeks before the application of the second medicament (or a combination of medicaments). Therefore, the two or more medicaments can be applied within a few minutes of each other, or within 1, 2, 3, 6, 9, 12, 15, 18 or 24 hours of each other, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 days, or within 2, 3, 4, 5, 6, 7, 8, 9 or a few weeks of each other. In some cases, there may even be a longer interval. Although in many cases, it is desired that the two or more medicaments used in combination therapy are present in the patient's body at the same time, this is not necessary.
[0136] Combination therapy can also include administering one or more of the agents used in the combination two or more times using different orders of the component agents. For example, if agent X and agent Y are used in combination, one can administer them sequentially in any combination one or more times, such as in the order of XYX, XXY, YXY, YYX, XXYY, etc. In addition, administration of two or more agents in the combination can precede or follow an administration dosage interval during which at least one of the combination agents is omitted from treatment.
[0137] Additional therapeutic agents that may be administered according to the present disclosure, for example, to treat mastocytosis or mastocytosis tumors include, but are not limited to, agents selected from the group consisting of: STAT5 inhibitors, including, but not limited to, ruxolitinib, tofacitinib, or fedratinib; BTK inhibitors, including, but not limited to, ibrutinib, PCI 29732, acalabrutinib or AVL-292; PI3 kinase inhibitors, including but not limited to idelalisib, dactolisib, pictilisib, LY294002, buparlisib, pilaralisib, duvelisib, PF-04691502, voxtalisib, omipalisib, gedatolisib, apitolisib or wortmannin; AKT kinase inhibitors, including but not limited to MK-2206, perifosine, GSK690693, GSK2141795, ipatasertib, AZD5363, afuresertib or AT7867; DNA methylation inhibitors, including but not limited to 5-azacytidine or 5-aza-2'-deoxycytidine; proteosome inhibitors, including but not limited to bortezomib, carfilzomib, MLN9708, ONX 0912; interferon alpha (IFN-); cladribine; and lysosomal agents, including but not limited to chloroquine, hydroxychloroquine or quinacrine.
[0138] In certain embodiments, the additional therapeutic agent is selected from 5-azacytidine, 5-aza-2'-deoxycytidine, and cladribine.
[0139] In certain embodiments, a subject in need thereof is treated with a combination of one or both of Compound A or a pharmaceutically acceptable salt thereof, a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) and 5-azacytidine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is bimetinib. In certain embodiments, the MAPKAP pathway inhibitor is uritinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib, or vemurafenib.
[0140] In certain embodiments, a subject in need thereof is treated with a combination of Compound A or a pharmaceutically acceptable salt thereof, a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120), and 5-aza-2'-deoxycytidine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is bimetinib. In certain embodiments, the MAPKAP pathway inhibitor is uritinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib, or vemurafenib.
[0141] In certain embodiments, a subject in need is treated with a combination of Compound A or a pharmaceutically acceptable salt thereof, a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120) and cladribine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is bimetinib. In certain embodiments, the MAPKAP pathway inhibitor is uritinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib, or vemurafenib. Additional therapeutic agents that may be administered according to the present disclosure include, but are not limited to, arsenic trioxide, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, enasidenib, idarubicin, quizartinib, mitoxantrone, thioguanine, or vincristine. In certain embodiments, a subject with AML is treated with a combination of Compound A, or a pharmaceutically acceptable salt thereof, and arsenic trioxide, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, ensidipine, idarubicin, quizartinib, mitoxantrone, thioguanine, or vincristine.
[0142] Pharmaceutical composition
[0143] Aspects of the present disclosure relate to treatment methods, which involve administering a combination of compounds disclosed herein, or one or more pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable diluent, excipient, or carrier. In a specific embodiment, the methods disclosed herein involve administering a first pharmaceutical composition and a second pharmaceutical composition, wherein the first pharmaceutical composition comprises a c-KIT inhibitor (e.g., Compound A or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent, excipient, or carrier), and the second pharmaceutical composition comprises a MAPKAP pathway inhibitor (e.g., Trametinib, Bimetinib, Uritinib, or LY3009120), and a pharmaceutically acceptable diluent, excipient, or carrier. In a specific embodiment, the methods disclosed herein involve administering a first pharmaceutical composition and a second pharmaceutical composition, wherein the first pharmaceutical composition comprises Compound B or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent, excipient, or carrier, and the second pharmaceutical composition comprises a MAPKAP pathway inhibitor (e.g., Trametinib, Bimetinib, Uritinib, or LY3009120), and a pharmaceutically acceptable diluent, excipient, or carrier. In certain embodiments, the methods disclosed herein involve administering a pharmaceutical composition comprising a ciKIT inhibitor (e.g., Compound A or a pharmaceutically acceptable salt thereof), a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120), and a pharmaceutically acceptable diluent, excipient, or carrier. In certain embodiments, the methods disclosed herein involve administering a pharmaceutical composition comprising Compound B or a pharmaceutically acceptable salt thereof, a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120), and a pharmaceutically acceptable diluent, excipient, or carrier.
[0144] When using pharmaceutical compositions of the compounds described herein, pharmaceutically acceptable carriers can be solid or liquid. Solid forms include powders, tablets, dispersible granules, capsules, cachets, and suppositories. Powders and tablets can contain from about 5% to about 95% of the active ingredient. Suitable solid carriers are known in the art, for example, magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of making various compositions can be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th ed., (1990), Mack Publishing Co., Easton, Pa., which is hereby incorporated by reference in its entirety.
[0145] Liquid preparations include solutions, suspensions and emulsions. For example, water or water-propylene glycol solutions are used for parenteral injections, or sweeteners and opacifiers are added for oral solutions, suspensions and emulsions. Liquid preparations may also include solutions for intranasal administration.
[0146] Liquid (particularly injectable) compositions can be prepared, for example, by dissolving, dispersing, etc. For example, the disclosed compounds are dissolved in or mixed with a pharmaceutically acceptable solvent (e.g., water, saline, aqueous dextrose, glycerol, ethanol, etc.) to form an injectable isotonic solution or suspension. Proteins such as albumin, chylomicrons, or serum proteins can be used to dissolve the disclosed compounds.
[0147] Parenteral injection administration is generally for subcutaneous, intramuscular or intravenous injection and infusion. Injections can be prepared in conventional forms, either as liquid solutions or suspensions or in solid forms suitable for dissolution in liquid prior to injection.
[0148] Aerosol formulations suitable for inhalation may also be used. These may include solutions and solids in powder form which may be combined with a pharmaceutically acceptable carrier such as an inert compressed gas, for example nitrogen.
[0149] Also contemplated for use are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral or parenteral administration. Such liquid forms include solutions, suspensions, and emulsions.
[0150] dose
[0151] In some embodiments of the treatment regimen in which Compound A or Compound B (or a pharmaceutically acceptable salt thereof) is used in combination with a MAPKAP pathway inhibitor (e.g., trametinib, bimetinib, uritinib, or LY3009120), the two therapeutic agents may be administered together or in a "dual regimen" in which the two therapeutic agents are administered and administered separately. When Compound A or B (or a pharmaceutically acceptable salt thereof) and a MAPKAP pathway inhibitor are administered separately, the typical dose of Compound A or Compound B (or a pharmaceutically acceptable salt thereof) administered to a subject in need of treatment is generally from about 5 mg per day to about 5000 mg per day, and in other embodiments, from about 50 mg per day to about 1000 mg per day. Other doses may be from about 10 mmol per day to about 250 mmol per day, from about 20 mmol per day to about 70 mmol per day, or even from about 30 mmol per day to about 60 mmol per day. When used for the effects shown, the effective dose of the disclosed compound ranges from about 0.5 mg to about 5000 mg of the disclosed compound required to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in the range of one amount to another amount in the dosage list. The typical recommended daily dosage regimen for oral administration can be in a single dose or in two to four divided doses, in the range of from about 1 mg / day to about 500 mg / day or 1 mg / day to 200 mg / day. In one embodiment, the typical daily oral dosage regimen is 150 mg.
[0152] In certain embodiments, the dosage of the MAPKAP pathway inhibitor is consistent with the previously disclosed dosage and / or the dosage approved for use by the Food and Drug Administration. In other embodiments, the dosage of the MAPKAP pathway inhibitor is less than the previously approved dosage, for example, about 20%, about 50%, or about 80% of the approved dosage. In certain embodiments, the dosage of trametinib is about .5 mg to 20 mg orally daily, for example, about 1 mg daily or about 2 mg daily. In certain embodiments, the dosage of cobimetinib is about 10 mg to 200 mg daily, for example, about 30 mg or about 60 mg daily. In certain embodiments, the dosage of bimetinib is about 10 mg to about 200 mg twice daily, for example, about 25 mg or about 45 mg twice daily. In certain embodiments, the dosage of selumetinib is about 10 mg to about 200 mg daily, or about 30 mg or about 75 mg twice daily.
[0153] The amount and frequency of administration of the compounds described herein and / or pharmaceutically acceptable salts thereof and other therapeutic agents will also be regulated according to the judgment of the attending clinician taking into account factors such as the age, condition and size of the patient and the severity of the symptoms being treated.
[0154] The compounds of the present disclosure (e.g., Compound A or Compound B (and pharmaceutically acceptable salts thereof), MAPKAP pathway inhibitors and other therapeutic agents) may be administered by any suitable route. The compounds may be administered orally (e.g., dietary) in the form of capsules, suspensions, tablets, pills, dragees, liquids, gels, syrups, slurries, and the like. Methods of encapsulating compositions (such as in hard gelatin or cyclodextrin coatings) are known in the art (Baker et al., "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986, which are hereby incorporated by reference in their entirety). The compounds may be administered to a subject in combination with an acceptable pharmaceutical carrier as part of a pharmaceutical composition. The formulation of the pharmaceutical composition will vary depending on the route of administration selected. Suitable pharmaceutical carriers may contain inert ingredients that do not interact with the compound. The carrier is biocompatible, i.e., non-toxic, non-inflammatory, non-immunogenic, and has no other adverse reactions at the site of administration.
[0155] Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a compound described herein (e.g., Compound A or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier, such as: a) a diluent, for example, purified water, triglyceride oils (such as hydrogenated or partially hydrogenated vegetable oils, or mixtures thereof), corn oil, olive oil, sunflower oil, safflower oil, fish oil (such as EPA or DHA, or their esters or triglycerides or mixtures thereof), omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and / or glycine; b) a lubricant, for example, silicon dioxide, talc, stearic acid, their magnesium or calcium salts, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and / or polyethylene glycol; also used in tablets; c) binders, for example, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or β-lactose, corn sweeteners, natural and synthetic gums (such as gum arabic), tragacanth or sodium alginate, waxes and / or polyvinylpyrrolidone, if necessary; d) disintegrants, for example, starch, agar, methylcellulose, bentonite, xanthan gum, alginic acid or its sodium salt, or effervescent mixtures; e) absorbents, colorants, flavors and sweeteners; f) emulsifiers or dispersants, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmulMCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifiers; and / or g) agents that enhance the absorption of the compound, such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.
[0156] If formulated as a fixed dose, such combination products employ the compounds described herein within the dosage range described herein or as known to those skilled in the art.
[0157] Since the compounds described herein (e.g., Compounds A and B and MAPKAP pathway inhibitors) are intended for use in pharmaceutical compositions, the skilled artisan will appreciate that they can be provided in substantially pure form (e.g., at least 60% pure, at least 75% pure, at least 85% pure, and at least 98% pure (w / w)). Pharmaceutical preparations can be in unit dosage form. In this form, the preparation is subdivided into appropriately sized unit doses containing an appropriate amount of Compound A or B, e.g., an effective amount to achieve the desired purpose as described herein.
[0158] Example
[0159] It has been found that treatment with a combination of Compound A or a pharmaceutically acceptable salt thereof and a MAPKAP pathway inhibitor unexpectedly and synergistically induces apoptosis of mast cells driven by mutant c-KIT, which is the cause of systemic mastocytosis. In addition, this combination therapy inhibits the proliferation of mastocytosis cells. In addition, the combination therapy disclosed herein appears to have a cytotoxic effect on mastocytosis, rather than just a cell growth inhibitory effect, as determined by caspase activation induced by the combination therapy. Characterization of this unexpected discovery was performed in biochemical assays and cell assays (including those described herein).
[0160] Therefore, the present disclosure is further illustrated by the following examples, which should not be construed as limiting the present disclosure to the scope or spirit of the specific procedures described herein. It should be understood that these examples are provided to illustrate certain embodiments, and are therefore not intended to limit the scope of the present disclosure. It should be further understood that, without departing from the spirit of the present disclosure and / or the scope of the appended claims, various other embodiments, modifications and equivalents thereof that may emerge to those skilled in the art may have to be sought.
[0161] Example 1. Treatment of mutant KIT mast cell lines with Compound A or Compound B inhibits cell proliferation and KIT phosphorylation in mastocytosis cell lines.
[0162] Studies were performed showing that treatment with either Compound A or Compound B inhibited cell proliferation of mutant KIT HMC1.1 KIT V560G and HMC1.2 KIT V560G / D816V mast cell lines. Assays were performed in 96-well plates seeded with 10,000 cells per well. Cells were treated with vehicle control, Compound A or its Compound B at varying concentrations, allowed to grow for 72 hours, and then cell proliferation was assessed.
[0163] Figure 1A is a graphical representation showing the relative percentage of cell proliferation determined for various concentrations of Compound A. Treatment with Compound A inhibited cell proliferation growth of HMC1.1 V560G and HMC1.2 V560G / D816V mast cell lines with IC50 values of 2.6 nM and 97 nM, respectively.
[0164] Figure 1B is a graph showing the relative percentage of cell proliferation determined for various concentrations of Compound B. Treatment with Compound B inhibited cell proliferation growth of HMC1.1 V560G and HMC1.2 V560G / D816V cell lines with IC50 values of 2.3 nM and 61 nM, respectively.
[0165] Example 2. Treatment with a combination of Compound A and trametinib induces apoptosis in mastocytosis cell lines.
[0166] Studies conducted have shown that treatment with a combination of Compound A and the MEK inhibitor trametinib induces apoptosis in the HMC1.2 KITV560G / D816V mastocytosis cell line. Assays were performed in 96-well plates seeded with 10,000 cells in each well. Cells were treated with vehicle control, Compound A, trametinib, or a combination thereof at different concentrations and grown for 24 hours. Apoptosis was assessed by measuring caspase 3 / 7 activity.
[0167] Figure 2A is a graphical representation showing the relative percentage of apoptosis determined for various treatments. Figure 2B is a matrix of synergy plots based on the combination index (CI) method described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). CI < 1 indicates synergy, CI = 1 indicates additivity, and CI > 1 indicates antagonism. Combination treatment with Compound A and the MEK inhibitor trametinib unexpectedly showed a strong synergistic effect to induce apoptosis of HMC1.2KIT V560G / D816V cells. Figure 2C is a combination index graph of CI, indicating that the combination of compound A and trametinib has a strong synergistic effect to induce apoptosis in HMC1.2 KIT V560G / D816V mast cells.
[0168] Example 3. Treatment with a combination of Compound B and trametinib induces apoptosis in mastocytosis cell lines.
[0169] Studies were also performed showing that treatment with a combination of Compound B and Trametinib induced apoptosis in the HMC1.2KIT V560G / D816V mastocytosis cell line. The assay was performed as described in Example 2. Apoptosis was assessed by measuring caspase 3 / 7 activity.
[0170] Figure 3A is a graphical representation showing the relative percentage of apoptosis determined for various treatments. Figure 3B is a matrix of synergy plots based on the combination index (CI) method described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). CI < 1 indicates synergy, CI = 1 indicates additive effect, and CI > 1 indicates antagonism. Combination treatment with compound B and the MEK inhibitor trametinib unexpectedly showed a strong synergistic effect to induce apoptosis of HMC1.2KIT V560G / D816V cells. Figure 3Cis a combination index graph of CI, indicating that the combination of compound B and trametinib has a strong synergistic effect to induce apoptosis in HMC1.2 KIT V560G / D816V mast cells.
[0171] Example 4. Treatment with a combination of Compound A and Bimetinib induces apoptosis in mastocytosis cell lines.
[0172] Treatment with the combination of Compound A and bimetinib also induced apoptosis in the HMC1.2 KIT V560G / D816V mastocytosis cell line. The assay was performed as described in Example 2. Apoptosis was assessed by measuring caspase 3 / 7 activity.
[0173] Figure 4A is a graphical representation showing the relative percentage of apoptosis determined for various treatments. Figure 4B is a matrix of synergy plots based on the Combination Index (CI) method described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). Combination treatment with Compound A and the MEK inhibitor bimetinib unexpectedly showed a strong synergistic effect to induce apoptosis in HMC1.2KIT V560G / D816V cells. Figure 4C is a combination index graph of CI, indicating that the combination of compound A and bimetinib has a strong synergistic effect to induce apoptosis of HMC1.2 KIT V560G / D816V mast cells.
[0174] Example 5. Treatment with a combination of Compound B and Bimetinib induces apoptosis in mastocytosis cell lines.
[0175] Figure 5A is a graphical representation showing the relative percentage of apoptosis determined for various treatments with Compound B and binimetinib. Figure 5B is a matrix of synergy plots based on the combination index (CI) method described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). CI < 1 indicates synergy, CI = 1 indicates additive effect, and CI > 1 indicates antagonism. Combination treatment with Compound B and the MEK inhibitor bimetinib unexpectedly showed a strong synergistic effect to induce apoptosis of HMC1.2 KIT V560G / D816V cells. Figure 5C is a combination index graph of CI, indicating that the combination of compound B and bimetinib has a strong synergistic effect to induce apoptosis of HMC1.2KIT V560G / D816V mast cells.
[0176] Example 6. Treatment with a combination of Compound A and cobimetinib induces apoptosis in mastocytosis cell lines.
[0177] Fig. 6A is a graphical representation showing the relative percentage of apoptosis determined for various treatments with Compound A and cobimetinib. Figure 6B is a matrix of synergy plots based on the Combination Index (CI) method described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). Combination treatment with Compound A and the MEK inhibitor cobimetinib unexpectedly showed a strong synergistic effect to induce apoptosis in HMC1.2 KIT V560G / D816V cells. Figure 6C is a combination index graph of CI, indicating that the combination of compound A and cobimetinib has a strong synergistic effect to induce apoptosis of HMC1.2 KITV560G / D816V mast cells.
[0178] Example 7. Treatment with a combination of Compound B and cobimetinib induces apoptosis in mastocytosis cell lines.
[0179] Fig. 7A is a graphical representation showing the relative percentage of apoptosis determined for various treatments with Compound B and cobimetinib. Figure 7B is a matrix of synergy plots based on the combination index (CI) method described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). CI < 1 indicates synergy, CI = 1 indicates additivity, and CI > 1 indicates antagonism. Combination treatment with Compound B and the MEK inhibitor cobimetinib unexpectedly showed a strong synergistic effect to induce apoptosis in HMC1.2 KIT V560G / D816V cells. Figure 7C is a combination index graph of CI, indicating that the combination of compound B and cobimetinib has a strong synergistic effect to induce apoptosis of HMC1.2KIT V560G / D816V mast cells.
[0180] Example 8. Treatment with a combination of Compound A and Uritinib induces apoptosis in mastocytosis cell lines.
[0181] Fig. 8A is a graphical representation showing the relative percentage of apoptosis determined for various treatments with Compound A and the ERK inhibitor Uritinib. Figure 8B is a matrix of synergy plots based on the Combination Index (CI) method described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). Combination treatment with Compound A and Uritinib unexpectedly showed a strong synergistic effect to induce apoptosis in HMC1.2 KIT V560G / D816V cells. Figure 8Cis a combination index plot of CI, indicating that the combination of compound A and uritinib has a strong synergistic effect to induce apoptosis of HMC1.2 KITV560G / D816V mast cells.
[0182] Example 9. Treatment with a combination of Compound B and Uritinib induces apoptosis in mastocytosis cell lines.
[0183] Combination treatment of Compound B and the ERK inhibitor Uritinib can be evaluated for induction of apoptosis in HMC1.2 KIT V560G / D816V mast cells. A matrix of synergy plots can be generated based on the combination index (CI) method as described by Chou and Talalay (1984), and the computer software of Chou and Martin (2005). Combination treatment of Compound B and Uritinib can be used to show synergy for inducing apoptosis in HMC1.2 KIT V560G / D816V cells. Combination index plots of CI can be used to demonstrate synergy of the combination of Compound B and Uritinib for inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells.
[0184] Example 10. Treatment with a combination of Compound A and SCH772984 induces apoptosis in mastocytosis cell lines.
[0185] The combination of Compound A and the ERK inhibitor SCH772984 can be evaluated for the induction of apoptosis of HMC1.2KIT V560G / D816V mast cells. Based on the combination index (CI) method as described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005), a matrix of synergy diagrams can be generated. The combination of Compound A and SCH772984 can be used to show the synergy for inducing apoptosis of HMC1.2 KIT V560G / D816V cells. The combination index diagram of CI can be used to demonstrate the synergy of the combination of Compound A and SCH772984 for inducing apoptosis of HMC1.2KIT V560G / D816V mast cells.
[0186] Example 11. Treatment with a combination of Compound B and SCH772984 induces apoptosis in mastocytosis cell lines.
[0187] The combination of compound B and the ERK inhibitor SCH772984 can be evaluated for the induction of apoptosis of HMC1.2KIT V560G / D816V mast cells. Based on the combination index (CI) method as described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005), a matrix of synergy diagrams can be generated. The combination of compound A and SCH772984 can be used to show the synergy for inducing apoptosis of HMC1.2 KIT V560G / D816V cells. The combination index diagram of CI can be used to demonstrate the synergy of the combination of compound B and SCH772984 for inducing apoptosis of HMC1.2KIT V560G / D816V mast cells.
[0188] Example 12. Treatment with a combination of Compound A and LY3009120 induces apoptosis in mastocytosis cell lines.
[0189] The combination of Compound A and RAF inhibitor LY3009120 can be evaluated for the induction of apoptosis of HMC1.2KIT V560G / D816V mast cells. Based on the combination index (CI) method as described by Chou and Talalay (1984), and the computer software of Chou and Martin (2005), a matrix of synergy diagrams can be generated. The combination of Compound A and LY3009120 can be used to show the synergy for inducing apoptosis of HMC1.2 KIT V560G / D816V cells. The combination index diagram of CI can be used to demonstrate the powerful synergy of the combination of Compound A and LY3009120 for inducing apoptosis of HMC1.2KIT V560G / D816V mast cells.
[0190] Example 13. Treatment with a combination of Compound B and LY3009120 induces apoptosis in mastocytosis cell lines.
[0191] The combination treatment of Compound B and RAF inhibitor LY3009120 can be evaluated for the induction of apoptosis of HMC1.2 KIT V560G / D816V mast cells. Based on the combination index (CI) method as described by Chou and Talalay (1984), and the computer software of Chou and Martin (2005), a matrix of synergy plots can be generated. Combination treatment of Compound B and LY3009120 can be used to show synergy for inducing apoptosis of HMC1.2 KIT V560G / D816V cells. Combination index plots of CI can be used to demonstrate the synergy of the combination of Compound B and LY3009120 for inducing apoptosis of HMC1.2 KIT V560G / D816V mast cells.
[0192] Example 14. Combination treatment with Compound A and Trametinib results in a synergistic reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0193] Studies were performed that showed that treatment with a combination of Compound A and the MEK inhibitor trametinib resulted in reduced colony outgrowth of HMC1.2 compared to treatment with either agent alone. 10,000 HMC1.2 cells were grown in soft agar and incubated for 10 days with various concentrations of Compound A, trametinib, or a combination of Compound A and trametinib. After an additional 5 days, drug treatment was removed and colony outgrowth of live cells was monitored.
[0194] Fig. 9A Figures are representative images of colony outgrowth of HMC1.2 mast cells after treatment with trametinib (0, 10, or 25 nM), compound A (0, 25, or 50 nM) as a single agent or as a matrix combination of different concentrations of compound A and different concentrations of trametinib. Single agent treatment with compound A or trametinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound A and trametinib resulted in less colony outgrowth 5 days after drug removal. The combination of compound A (25 nM) and trametinib (25 nM) resulted in complete eradication of colony outgrowth 5 days after drug removal. The combination of compound A (50 nM) and trametinib (10 or 25 nM) unexpectedly resulted in complete eradication of outgrowth of live HMC1.2 cells to the limit of detection as determined by visualization with a 5X objective lens 5 days after drug removal, whereas no eradication was observed after treatment with single agent compound A or single agent trametinib. Further extension of colony outgrowth to an additional 8 days after drug removal (13 days total) maintained eradication to the detection limit of colony outgrowth using a combination of Compound A (50 nM) and trametinib (10 and 25 nM). However, after incubation for an additional 8 days with a combination of Compound A (25 nM) and trametinib (25 nM), approximately 15-20 colonies grew out. ( Fig. 9A right).
[0195] Fig. 9B Is quantitative in Fig. 9A Schematic representation of colony outgrowth of HMC1.2 mast cells after various treatments. Combination treatment with 50 nM of Compound A and 10 nM or 25 nM of trametinib unexpectedly resulted in eradication of colony outgrowth to the limit of detection as determined by visualization with a 5X objective (see arrows, Fig. 9BThe combined treatment with 25 nM Compound A and 25 nM Trametinib unexpectedly resulted in eradication of colony outgrowth to the limit of detection as determined by visualization with a 5X objective (see arrows, Fig. 9B ), no eradication was observed after treatment with either single-agent Compound A or trametinib.
[0196] Example 15. Combination treatment with Compound B and Trametinib results in a synergistic reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0197] As described in Example 14, studies were also conducted using Compound B and the MEK inhibitor trametinib to evaluate the reduction of colony outgrowth of HMC1.2 cells.
[0198] Fig. 10A Representative pictures of colony outgrowth of HMC1.2 mast cells after treatment with trametinib (0, 10 or 25 nM), compound B (0, 25 or 50 nM) as single agents or as matrix combinations of different concentrations of compound B and different concentrations of trametinib. Single agent treatment with compound B or trametinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound B and trametinib resulted in less colony outgrowth 5 days after drug removal. The combination of compound B (25 nM) and trametinib (25 nM) resulted in a significant reduction in outgrowth of viable HMC1.2 cells 5 days after drug removal. The combination of Compound B (50 nM) and trametinib (10 or 25 nM) unexpectedly resulted in complete eradication of outgrowth of live HMC1.2 cells to the limit of detection as determined by visualization with a 5X objective 5 days after drug removal, whereas no eradication was observed following treatment with either single-agent Compound B or single-agent trametinib. Further extension of colony outgrowth to an additional 8 days after drug removal (13 days total) maintained eradication to the limit of detection of colony outgrowth using the combination of Compound B (50 nM) and trametinib (25 nM).
[0199] Fig. 10B Is quantitative in Fig. 10A Schematic representation of colony outgrowth of HMC1.2 mast cells after various treatments. Combination treatment with 50 nM Compound B and 10 nM or 25 nM trametinib unexpectedly resulted in eradication of colony outgrowth to the limit of detection as determined by visualization with a 5X objective, whereas no eradication was observed after treatment with either single agent Compound B or trametinib (see arrows, Fig. 10B ).
[0200] Example 16. Combination treatment with Compound A and Bimetinib results in a synergistic reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0201] Fig.11A Figures are representative images of colony outgrowth of HMC1.2 mast cells after treatment with bimetinib (0, 250 or 500 nM), compound A (0, 25 or 50 nM) as a single agent or as a matrix combination of different concentrations of compound A and different concentrations of bimetinib. Single agent treatment with compound A or bimetinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound A and bimetinib resulted in less colony outgrowth 5 days after drug removal. The combination of compound A (25 nM) and bimetinib (250 nM) resulted in a significant reduction in the outgrowth of viable HMC1.2 cells 5 days after drug removal. The combination of Compound A (50 nM) and Bimetinib (250 nM or 500 nM) unexpectedly resulted in complete eradication of outgrowth of live HMC1.2 cells to the limit of detection as determined by visualization with a 5X objective lens 5 days after drug removal, whereas no eradication was observed after treatment with either Compound A alone or Bimetinib alone. Further extension of colony outgrowth to an additional 8 days (13 days total) after drug removal still maintained eradication to the limit of detection of colony outgrowth using the combination of Compound A (50 nM) and Bimetinib (500 nM). However, with the combination of Compound A (50 nM) and Bimetinib (250 nM), approximately 10-15 colonies grew out.
[0202] Fig. 11B Is quantitative in Fig.11A Graphs of colony outgrowth of HMC1.2 mast cells after various treatments. Combination treatment with 50 nM Compound A and 250 nM or 500 nM bimetinib unexpectedly resulted in eradication of colony outgrowth to the limit of detection as determined by visualization with a 5X objective, whereas no eradication was observed after treatment with either single agent Compound A or bimetinib (see arrows, Fig. 11B ).
[0203] Example 17. Combination treatment with Compound B and Bimetinib results in a synergistic reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0204] Fig. 12AFigures are representative images of colony outgrowth of HMC1.2 mast cells after treatment with bimetinib (0, 250 or 500 nM), compound B (0, 25 or 50 nM) as a single agent or as a matrix combination of different concentrations of compound B and different concentrations of bimetinib. Single agent treatment with compound B or bimetinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound B and bimetinib resulted in less colony outgrowth 5 days after drug removal. The combination of compound B (25 nM) and bimetinib (250 nM) resulted in a significant reduction in the outgrowth of live HMC1.2 cells 5 days after drug removal. The combination of compound B (25 nM) and bimetinib (500 nM) resulted in complete eradication of the outgrowth of live HMC1.2 cells 5 days after drug removal to the limit of detection as determined by visualization with a 5X objective. The combination of Compound B (50 nM) and bimetinib (250 nM or 500 nM) unexpectedly resulted in complete eradication of outgrowth of live HMC1.2 cells to the detection limit as determined by visualization with a 5X objective 5 days after drug removal, whereas no eradication was observed following treatment with either single-agent Compound B or single-agent bimetinib. Further extension of colony outgrowth to an additional 8 days after drug removal (13 days total) maintained eradication to the detection limit of colony outgrowth using the combination of Compound B (50 nM) and bimetinib (250 or 500 nM) and the combination of Compound B (25 nM) and bimetinib (500 nM).
[0205] Fig. 12B Is quantitative in Fig. 12A Graphs of colony outgrowth of HMC1.2 mast cells after various treatments. Treatment with a combination of 25 nM Compound B and 500 nM bimetinib and 50 nM Compound B and 250 nM or 500 nM bimetinib unexpectedly resulted in eradication of colony outgrowth to the limit of detection as determined by visualization with a 5X objective, whereas no eradication was observed after treatment with either single agent Compound B or bimetinib (see arrows, Fig. 12B ).
[0206] Example 18. Combination treatment with Compound A and cobimetinib results in a synergistic reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0207] Fig.13ARepresentative pictures of colony outgrowth of HMC1.2 mast cells after treatment with cobimetinib (0, 25 or 50 nM), Compound A (0, 25 or 50 nM) as single agents or as matrix combinations of different concentrations of Compound A and different concentrations of cobimetinib. Single agent treatment with Compound A or cobimetinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of Compound A and cobimetinib resulted in less colony outgrowth 5 days after drug removal compared to either single agent treatment. The combination of Compound A (50 nM) and cobimetinib (25 or 50 nM) resulted in a significant reduction in outgrowth of live HMC1.2 cells 5 days after drug removal.
[0208] Fig. 13B Is quantitative in Fig.13A Graphical representation of colony outgrowth of HMC1.2 mast cells after various treatments of . Combination treatment with 50 nM Compound A and 25 nM or 50 nM cobimetinib resulted in a significant reduction in colony outgrowth compared to either single agent Compound A or cobimetinib.
[0209] Example 19. Combination treatment with Compound B and cobimetinib results in a synergistic reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0210] Fig.14A Representative pictures of colony outgrowth of HMC1.2 mast cells after treatment with cobimetinib (0, 25 or 50 nM), compound B (0, 25 or 50 nM) as single agents or as matrix combinations of different concentrations of compound B and different concentrations of cobimetinib. Single agent treatment with compound B or cobimetinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound B and cobimetinib resulted in less colony outgrowth 5 days after drug removal compared to either single agent treatment. The combination of compound B (50 nM) and cobimetinib (25 or 50 nM) resulted in a significant reduction in outgrowth of live HMC1.2 cells 5 days after drug removal.
[0211] Fig. 14B Is quantitative in Fig.14A Graphical representation of colony outgrowth of HMC1.2 mast cells after various treatments of . Combination treatment with 50 nM Compound B and 25 nM or 50 nM cobimetinib resulted in a significant reduction in colony outgrowth compared to either single agent Compound B or cobimetinib.
[0212] Example 20. Treatment with the combination of Compound A and the ERK inhibitor Uritinib results in a reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0213] According to the method of Example 14, the combination treatment of Compound A and Uritinib can be evaluated for inhibition of colony outgrowth of the HMC1.2 KITD816V mast cell line.
[0214] Example 21. Treatment with the combination of Compound B and the ERK inhibitor Uritinib results in a reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0215] According to the method of Example 14, the combined treatment of Compound B and Uritinib can be evaluated for inhibition of colony outgrowth of the HMC1.2 KITD816V mast cell line.
[0216] Example 22. Treatment with a combination of Compound A and the RAF inhibitor LY3009120 results in a reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0217] According to the method of Example 14, the combined treatment of Compound A and the RAF inhibitor LY3009120 can be evaluated for inhibition of colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0218] Example 23. Treatment with a combination of Compound B and LY3009120 results in a reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0219] According to the method of Example 14, the combined treatment of Compound B and the RAF inhibitor LY3009120 can be evaluated for inhibition of colony outgrowth of the HMC1.2 KIT D816V mast cell line.
[0220] Example 24. Treatment with a combination of Compound A and the MEK inhibitor trametinib induces apoptosis in the mutant N-ras G12D-transfected HMC1.2 KIT V560G / D816V mastocytosis cell line
[0221] Studies conducted have shown that treatment with a combination of Compound A and Trametinib induces apoptosis of HMC1.2 V560G / D816V cells transfected with mutant N-ras G12D. The assay was performed in 96-well plates seeded with 10,000 cells in each well. Cells were treated with vehicle control, Compound A, Trametinib, or a combination thereof at different concentrations and grown for 24 and 48 hours. Apoptosis was assessed by measuring caspase 3 / 7 activity.
[0222] Fig.15AIs a graphical representation showing the relative percentage of caspase activity determined for various treatments at 24 hours. Treatment with a combination of Compound A and Trametinib for 24 hours induces apoptosis of HMC1.2 V560G / D816V cells transfected with an empty vector (EV) (left panel) or HMC1.2 V560G / D816V cells transfected with mutant N-ras G12D (right panel). The combination of Compound A and Trametinib results in a synergistic increase in apoptosis of EV-transfected cells and N-ras G12D-transfected HMC1.2 cells.
[0223] Fig. 15B It is a graphical representation showing the relative percentage of caspase activity determined for various treatments at 48 hours. Treatment with a combination of compound A and trametinib for 48 hours induced apoptosis of HMC1.2 V560G / D816V cells transfected with an empty vector (EV) (left figure) or HMC1.2 V560G / D816V cells transfected with a mutant N-ras G12D (right figure). The combination of compound A and trametinib resulted in a synergistic increase in apoptosis of EV-transfected cells and N-ras G12D-transfected HMC1.2 cells. The apoptosis of N-ras-transfected cells was higher than that of EV-transfected cells.
[0224] Example 25. Treatment with a combination of Compound A and the MEK inhibitor cobimetinib induces apoptosis in the mutant N-ras G12D-transfected HMC1.2 KIT V560G / D816V mastocytosis cell line
[0225] Fig.16A It is a graphical representation showing the relative percentage of caspase activity determined for various treatments at 24 hours. Treatment with a combination of compound A and cobimetinib for 24 hours induced apoptosis of HMC1.2 V560G / D816V cells transfected with an empty vector (EV) (left figure) or HMC1.2 V560G / D816V cells transfected with a mutant N-ras G12D (right figure). The combination of compound A and cobimetinib resulted in a synergistic increase in apoptosis of HMC1.2 cells transfected with EV and N-ras G12D. The apoptosis of cells transfected with N-ras was higher than that of cells transfected with EV.
[0226] Fig. 16BIt is a diagram showing the relative percentage of caspase activity determined for various treatments at 48 hours. Treatment with a combination of compound A and cobimetinib for 48 hours induced apoptosis of HMC1.2 V560G / D816V cells transfected with an empty vector (EV) (left figure) or HMC1.2 V560G / D816V cells transfected with a mutant N-ras G12D (right figure). The combination of compound A and cobimetinib resulted in a synergistic increase in apoptosis of HMC1.2 cells transfected with EV and N-ras G12D. The apoptosis of cells transfected with N-ras was higher than that of cells transfected with EV.
[0227] Example 26. Combination treatment with Compound A and the MEK inhibitor trametinib results in a synergistic reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line transfected with N-ras G12D or empty vector.
[0228] Studies conducted showed that combined treatment with Compound A and trametinib resulted in reduced colony outgrowth of HMC1.2 transfected with empty vector (EV) or transfected with N-ras G12D compared to treatment with either single agent. HMC1.2 cells were incubated with various concentrations of Compound A, trametinib, or a combination of Compound A and trametinib for 10 days. After an additional 5 or 13 days, drug treatment was removed and colony outgrowth of live cells was monitored.
[0229] Fig.17A Representative images of colony outgrowth of EV-transfected HMC1.2 mast cells after treatment with trametinib (0, 1, 10, or 25 nM), compound A (0, 25, or 50 nM) as single agents or as matrix combinations of different concentrations of compound A and different concentrations of trametinib. Single agent treatment with compound A or trametinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound A and trametinib resulted in less colony outgrowth 5 days after drug removal. The combination of compound A (50 nM) and trametinib (1 nM) resulted in a significant reduction in colony outgrowth in combination with 1 nM trametinib compared to single agent compound A or single agent trametinib. The combination of Compound A (50 nM) and trametinib (10 or 25 nM) unexpectedly resulted in complete eradication of outgrowth of live HMC1.2 cells to the limit of detection as determined by visualization with a 5X objective 5 days after drug removal, whereas no eradication was observed following treatment with either single-agent Compound A or single-agent trametinib. Colony outgrowth was further extended for an additional 8 days after drug removal (a total of 13 days after drug removal) while still maintaining eradication to the limit of detection of colony outgrowth using the combination of Compound A (50 nM) and trametinib (25 nM).
[0230] Fig. 17B Is quantitative in Fig.17A Schematic representation of colony outgrowth of EV-transfected HMC1.2 mast cells after various treatments. Combination treatment with 50 nM Compound A and 10 nM or 25 nM trametinib unexpectedly resulted in eradication of colony outgrowth to the limit of detection as determined by visualization with a 5X objective, whereas no eradication was observed after treatment with either single agent Compound A or trametinib (see arrows, Fig. 17B ).
[0231] Fig. 17C Representative images of colony outgrowth of N-ras G12D transfected HMC1.2 cells after treatment with trametinib (0, 1, 10 or 25 nM), compound A (0, 25 or 50 nM) as single agents or as matrix combinations of different concentrations of compound A and trametinib. Single agent treatment with compound A or trametinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound A and trametinib resulted in less colony outgrowth 5 days after drug removal. The combination of Compound A (25 nM) and trametinib (25 nM) resulted in a significant reduction in the outgrowth of live HMC1.2 cells 5 days after drug removal, and the combination of Compound A (50 nM) and trametinib (10 or 25 nM) unexpectedly resulted in complete eradication of the outgrowth of live N-ras G12D-transfected HMC1.2 cells 5 days after drug removal to the limit of detection as determined by visualization with a 5X objective, whereas no eradication was observed after treatment with either single-agent Compound A or trametinib. The eradication of colony outgrowth with the combination of Compound A (50 nM) and trametinib (25 nM) was further extended for an additional 8 days after drug removal (a total of 13 days after drug removal). Fig. 17C ).
[0232] Fig.17D Is quantitative from Fig. 17C . Combination treatment with Compound A and trametinib resulted in better blockade of colony outgrowth than with any single agent treatment. Combination treatment with 50 nM Compound A and 10 nM or 25 nM trametinib unexpectedly resulted in eradication of colony outgrowth to the limit of detection as determined by visualization with a 5X objective lens 5 days after drug removal, whereas no eradication was observed after treatment with any single agent Compound A or trametinib (see arrows, Fig.17D ).
[0233] Example 27. Combination treatment with Compound A and cobimetinib results in a synergistic reduction in colony outgrowth of the HMC1.2 KIT D816V mast cell line transfected with N-ras G12D or empty vector.
[0234] Studies conducted showed that combined treatment with Compound A and cobimetinib resulted in reduced colony outgrowth of HMC1.2 transfected with empty vector (EV) or transfected with N-ras G12D compared to treatment with either single agent. HMC1.2 cells were incubated with various concentrations of Compound A, cobimetinib, or a combination of Compound A and cobimetinib for 10 days. After an additional 5 or 10 days, drug treatment was removed and colony outgrowth of live cells was monitored.
[0235] Fig.18A Representative images of colony outgrowth of EV-transfected HMC1.2 mast cells after treatment with cobimetinib (25 or 50 nM), compound A (0, 25 or 50 nM) as single agents or as matrix combinations of different concentrations of compound A and different concentrations of cobimetinib. Single agent treatment with compound A or cobimetinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound A and cobimetinib resulted in less colony outgrowth 5 days after drug removal. The combination of compound A (25 nM) and cobimetinib (25 and 50 nM) resulted in a significant reduction in the outgrowth of viable HMC1.2 cells 5 days after drug removal. The combination of Compound A (50 nM) and cobimetinib (50 nM) unexpectedly resulted in complete eradication of outgrowth of live HMC1.2 cells to the limit of detection as determined by visualization with a 5X objective 5 days after removal of drug treatment, whereas no eradication was observed after treatment with either single-agent Compound A or single-agent cobimetinib. Colony outgrowth was further extended for an additional 5 days after removal of drug treatment (a total of 10 days after drug removal) while still maintaining eradication to the limit of detection of colony outgrowth using the combination of Compound A (50 nM) and cobimetinib (50 nM).
[0236] Fig.18B Is quantitative in Fig.18A Schematic representation of colony outgrowth of EV-transfected HMC1.2 mast cells after various treatments. Combination treatment with 50 nM Compound A and 50 nM cobimetinib unexpectedly resulted in eradication of colony outgrowth to the limit of detection as determined by visualization with a 5X objective, whereas no eradication was observed after treatment with either single agent Compound A or cobimetinib (see arrows, Fig.18B ).
[0237] Fig.18CFigures are representative images of colony outgrowth of HMC1.2 mast cells transfected with N-ras G12D after treatment with cobimetinib (0, 25 or 50 nM), compound A (0, 25 or 50 nM) as a single agent or as a matrix combination of different concentrations of compound A and different concentrations of cobimetinib. Single agent treatment with compound A or cobimetinib resulted in colony outgrowth at all concentrations 5 days after drug removal, whereas the combination of compound A and cobimetinib resulted in less colony outgrowth 5 days after drug removal. The combination of compound A (25 nM) and cobimetinib (25 and 50 nM) resulted in a significant reduction in the outgrowth of viable HMC1.2 cells 5 days after drug removal. The combination of Compound A (50 nM) and cobimetinib (25 or 50 nM) unexpectedly resulted in complete eradication of outgrowth of live HMC1.2 cells to the limit of detection as determined by visualization with a 5X objective 5 days after removal of drug treatment, whereas no eradication was observed after treatment with either single-agent Compound A or single-agent cobimetinib. Further extension of colony outgrowth to an additional 10 days after removal of drug treatment maintained eradication to the limit of detection of colony outgrowth using a combination of Compound A (50 nM) and cobimetinib (25 or 50 nM).
[0238] Fig.18D Is quantitative from Fig.18C . The combined treatment with Compound A and Cobimetinib resulted in better blocking of colony growth than with any single-agent treatment. The combined treatment with 50 nM Compound A and 25 or 50 nM Cobimetinib unexpectedly resulted in eradication of colony growth to the limit of detection as determined by 5X objective lens visualization after 5 days of drug removal, whereas no eradication was observed after treatment with any single-agent Compound A or Cobimetinib (see arrows, Fig.18D ).
[0239] Equivalent
[0240] Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments described specifically in this disclosure. Such equivalents are intended to be encompassed within the scope of the following claims.
Claims
1. A method of treating mastocytosis in a patient in need thereof, the method comprising administering to the patient: a. an effective amount of a c-KIT inhibitor; and b. An effective amount of one or more MAPKAP pathway inhibitors.
2. The method of claim 1, wherein the MAPKAP pathway inhibitor is selected from the group consisting of: mitogen-activated protein kinase (MEK inhibitor), extracellular signal-regulated kinase inhibitor (ERK inhibitor), and rapidly accelerated fibrosarcoma (RAF) kinase inhibitor.
3. The method of claim 1 or 2, wherein the mastocytosis has a c-KIT mutation.
4. The method of any one of claims 1-3, wherein the c-KIT mutation is an activating mutation.
5. The method of any one of claims 1-4, wherein the mastocytosis comprises mast cells having a primary mutation in exon 17 of the c-KIT gene.
6. The method of claim 5, wherein the primary mutation is the c-KIT D816 mutation.
7. The method of claim 5 or 6, wherein the primary mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and del419.
8. The method of any one of claims 5-6, wherein the primary mutation is D816V.
9. The method of any one of claims 1-8, wherein the mastocytosis comprises mast cells having a secondary c-KIT mutation.
10. The method of claim 9, wherein the secondary c-KIT mutation is in one of exons 9, 11, 13, or 17.
Citation Information
Patent Citations
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US8461179B1
